Corcept Therapeutics Incorporated

Stock Chart, Company Information, and Scan Results

$69(as of Aug 1, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Corcept Therapeutics Incorporated Company Information, Fundamentals, and Technical Indicators

Stock Price$69
Ticker SymbolCORT
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees500
CountyUSA
Market Cap$7,270.7M
EBIDTA102.1M
10-Day Moving Average68.69
P/E Ratio62.99
20-Day Moving Average69.92
Forward P/E Ratio53.76
50-Day Moving Average71.76
Earnings per Share1.12
200-Day Moving Average63.51
Profit Margin17.80%
RSI46.73
Shares Outstanding105.4M
ATR2.84
52-Week High117.33
Volume2,107,380
52-Week Low32.33
Most Recent Support Level67.75
Book Value635.8M
Most Recent Resistance Level70.74
P/B Ratio13.08
Upper Keltner76.30
P/S Ratio11.61
Lower Keltner63.54
Debt-to-Equity Ratio76.30
Next Earnings Date10/29/2025
Cash Surplus-41.9M
Next Ex-Dividend DateUnknown

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated In Our Stock Scanner

As of Aug 04, 2025
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.